Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection
NCT07446582
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this observational clinical study is to learn if DeepMSI AI detects age-related macular degeneration (AMD) biomarkers with sensitivity and specificity equivalent to experienced clinicians in adults over 40 years old. The main questions it aims to answer are: Does DeepMSI AI detect AMD biomarkers with sensitivity equivalent to experienced clinicians? Does DeepMSI AI detect AMD biomarkers with specificity equivalent to experienced clinicians?
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Age-Related (Dry) Macular Degeneration
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- AI-Spectral
- Last updated on ClinicalTrials.gov
- March 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 1
- Contact Lens & Vision · Woodbridge, NJ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.